{"id":66860,"date":"2026-04-04T00:00:00","date_gmt":"2026-04-03T18:30:00","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=66860"},"modified":"2026-04-03T15:04:22","modified_gmt":"2026-04-03T09:34:22","slug":"aurobindo-pharma-q4-results-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/","title":{"rendered":"Aurobindo Pharma Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &#038; Share Price Target"},"content":{"rendered":"<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Get Free Investment Predictions and Aurobindo Pharma Research at Univest<\/strong><\/a><\/p><p>Aurobindo Pharma is scheduled to announce its Q4 FY26 (January\u2013March 2026) financial results on May 5, 2026. As of April 2026, the stock trades around Rs.1,010 on NSE with a market capitalisation of Rs.59,200 Cr. The 52-week range is Rs.Rs.940 (low) to Rs.Rs.1,450 (high), and the trailing P\/E is approximately 14x.<\/p><p>India&#8217;s pharmaceutical sector in Q4 FY26 is navigating a complex environment \u2014 strong domestic branded growth offset by US generics pricing pressure and selective USFDA inspection risk. Aurobindo Pharma&#8217;s Q4 FY26 results will be watched for US revenue, domestic IPM performance, and pipeline updates.<\/p><p>This article covers Aurobindo Pharma&#8217;s Q4 FY26 analyst estimates, Q3 FY26 actual performance for context, key catalysts and risks to watch, technical levels, and the 12-month analyst share price target. For live research and expert analysis on Aurobindo Pharma, visit <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#About_Aurobindo_Pharma\" title=\"About Aurobindo Pharma\">About Aurobindo Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#Aurobindo_Pharma_Q4_FY26_Estimates_%E2%80%94_What_Analysts_Expect\" title=\"Aurobindo Pharma Q4 FY26 Estimates \u2014 What Analysts Expect\">Aurobindo Pharma Q4 FY26 Estimates \u2014 What Analysts Expect<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#Key_Catalysts_to_Watch_in_Aurobindo_Pharma_Q4_FY26_Results\" title=\"Key Catalysts to Watch in Aurobindo Pharma Q4 FY26 Results\">Key Catalysts to Watch in Aurobindo Pharma Q4 FY26 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#1_Injectable_expansion_Phase_III_facility\" title=\"1. Injectable expansion Phase III facility\">1. Injectable expansion Phase III facility<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#2_Europe_injectables_growing\" title=\"2. Europe injectables growing\">2. Europe injectables growing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#3_Antibiotics_volumes_steady\" title=\"3. Antibiotics volumes steady\">3. Antibiotics volumes steady<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#Key_Risks_for_Aurobindo_Pharma_Q4_FY26_Results\" title=\"Key Risks for Aurobindo Pharma Q4 FY26 Results\">Key Risks for Aurobindo Pharma Q4 FY26 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#Aurobindo_Pharma_Q3_FY26_Performance_%E2%80%94_Setting_the_Context\" title=\"Aurobindo Pharma Q3 FY26 Performance \u2014 Setting the Context\">Aurobindo Pharma Q3 FY26 Performance \u2014 Setting the Context<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#Technical_Analysis_%E2%80%94_Aurobindo_Pharma_Share_Price_Levels\" title=\"Technical Analysis \u2014 Aurobindo Pharma Share Price Levels\">Technical Analysis \u2014 Aurobindo Pharma Share Price Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#Aurobindo_Pharma_Share_Price_Target_%E2%80%94_Analyst_Estimates\" title=\"Aurobindo Pharma Share Price Target \u2014 Analyst Estimates\">Aurobindo Pharma Share Price Target \u2014 Analyst Estimates<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#Short-Term_Target_3%E2%80%936_months\" title=\"Short-Term Target (3\u20136 months)\">Short-Term Target (3\u20136 months)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#12-Month_Analyst_Consensus_Target\" title=\"12-Month Analyst Consensus Target\">12-Month Analyst Consensus Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#Long-Term_View_FY27%E2%80%93FY28\" title=\"Long-Term View (FY27\u2013FY28)\">Long-Term View (FY27\u2013FY28)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#What_to_Watch_on_Results_Day\" title=\"What to Watch on Results Day\">What to Watch on Results Day<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#When_is_Aurobindo_Pharma_Q4_FY26_results_date\" title=\"When is Aurobindo Pharma Q4 FY26 results date?\">When is Aurobindo Pharma Q4 FY26 results date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#What_is_the_Aurobindo_Pharma_Q4_FY26_revenue_estimate\" title=\"What is the Aurobindo Pharma Q4 FY26 revenue estimate?\">What is the Aurobindo Pharma Q4 FY26 revenue estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#What_is_the_Aurobindo_Pharma_share_price_target\" title=\"What is the Aurobindo Pharma share price target?\">What is the Aurobindo Pharma share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#Is_Aurobindo_Pharma_a_good_buy_before_Q4_results\" title=\"Is Aurobindo Pharma a good buy before Q4 results?\">Is Aurobindo Pharma a good buy before Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#What_should_I_watch_for_in_Aurobindo_Pharma_Q4_FY26_results\" title=\"What should I watch for in Aurobindo Pharma Q4 FY26 results?\">What should I watch for in Aurobindo Pharma Q4 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#Where_can_I_find_Aurobindo_Pharma_Q4_FY26_results\" title=\"Where can I find Aurobindo Pharma Q4 FY26 results?\">Where can I find Aurobindo Pharma Q4 FY26 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q4-results-2026\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Aurobindo_Pharma\"><\/span><strong>About Aurobindo Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Aurobindo Pharma (NSE: AUROPHARMA) is a Pharma company listed on the National Stock Exchange and Bombay Stock Exchange. It is a constituent of major benchmark indices and is widely tracked by domestic and foreign institutional investors. Q4 FY26 (January to March 2026) is historically a seasonally important quarter for most sectors, and the results will provide crucial data for full-year FY26 performance assessment and FY27 outlook.<\/p><p>Aurobindo Pharma Q4 FY26 key estimates \u2014 revenue, PAT, analyst target and result date<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Aurobindo_Pharma_Q4_FY26_Estimates_%E2%80%94_What_Analysts_Expect\"><\/span><strong>Aurobindo Pharma Q4 FY26 Estimates \u2014 What Analysts Expect<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"931\" height=\"486\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/03145906\/image-175.jpeg\" alt=\"Aurobindo Pharma Q4 FY26 Estimates \u2014 What Analysts Expect\" class=\"wp-image-66862\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/03145906\/image-175.jpeg 931w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/03145906\/image-175-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/03145906\/image-175-768x401.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/03145906\/image-175-900x470.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/03145906\/image-175-600x313.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/03145906\/image-175-150x78.jpeg 150w\" sizes=\"(max-width: 931px) 100vw, 931px\" \/><\/figure><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Tap to Access Best Research Pieces on Aurobindo Pharma at Univest<\/strong><\/a><\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Context<\/strong><\/td><\/tr><tr><td>Revenue \/ Key Metric<\/td><td>Rs.7,400\u20137,800 Cr<\/td><td>Rs.7,249 Cr<\/td><td>Sequential and YoY trend<\/td><\/tr><tr><td>PAT \/ Profitability<\/td><td>Rs.680\u2013750 Cr<\/td><td>Rs.694 Cr<\/td><td>Bottom-line estimate<\/td><\/tr><tr><td>Margin \/ Key Ratio<\/td><td>18\u201319%<\/td><td>See article<\/td><td>Operational efficiency<\/td><\/tr><tr><td>Results Date<\/td><td>May 5, 2026<\/td><td>\u2014<\/td><td>Board meeting for approval<\/td><\/tr><tr><td>12-Month Analyst Target<\/td><td>Rs.1,050\u20131,320<\/td><td>\u2014<\/td><td>Buy<\/td><\/tr><\/tbody><\/table><\/figure><p>Source: Analyst consensus, Aurobindo Pharma Q3 FY26 earnings release, NSE\/BSE filings \u2014 April 2026. Estimates are projections only.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Catalysts_to_Watch_in_Aurobindo_Pharma_Q4_FY26_Results\"><\/span><strong>Key Catalysts to Watch in Aurobindo Pharma Q4 FY26 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here \u2014 Get Free Investment Predictions<\/strong><\/a><\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_Injectable_expansion_Phase_III_facility\"><\/span><strong>1. Injectable expansion Phase III facility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This catalyst could meaningfully drive Aurobindo Pharma&#8217;s Q4 FY26 performance and the market&#8217;s reaction to the results. Analysts will scrutinise management commentary on this point closely during the earnings call and investor presentation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Europe_injectables_growing\"><\/span><strong>2. Europe injectables growing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This catalyst could meaningfully drive Aurobindo Pharma&#8217;s Q4 FY26 performance and the market&#8217;s reaction to the results. Analysts will scrutinise management commentary on this point closely during the earnings call and investor presentation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Antibiotics_volumes_steady\"><\/span><strong>3. Antibiotics volumes steady<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This catalyst could meaningfully drive Aurobindo Pharma&#8217;s Q4 FY26 performance and the market&#8217;s reaction to the results. Analysts will scrutinise management commentary on this point closely during the earnings call and investor presentation.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Risks_for_Aurobindo_Pharma_Q4_FY26_Results\"><\/span><strong>Key Risks for Aurobindo Pharma Q4 FY26 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><ul class=\"wp-block-list\"><li>USFDA Andhra Pradesh plants under scrutiny<\/li>\n\n<li>US generics pricing erosion<\/li>\n\n<li>High regulatory compliance costs<\/li><\/ul><p>Monitor Aurobindo Pharma&#8217;s live fundamentals, FII\/DII activity, and sector comparison on the <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Aurobindo_Pharma_Q3_FY26_Performance_%E2%80%94_Setting_the_Context\"><\/span><strong>Aurobindo Pharma Q3 FY26 Performance \u2014 Setting the Context<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>To understand Q4 FY26 expectations, it is important to contextualise Q3 FY26 (October\u2013December 2025) performance. Aurobindo Pharma reported revenue of Rs.7,249 Cr and PAT of Rs.694 Cr in Q3 FY26, with a key margin metric of See article. This performance provides the sequential base against which Q4 FY26 results will be measured \u2014 both by the company&#8217;s own guidance (where applicable) and by analyst expectations.<\/p><p>The Q4 FY26 estimate of Rs.7,400\u20137,800 Cr in revenue and Rs.680\u2013750 Cr in PAT implies sequential growth \u2014 driven by the sector tailwinds and company-specific execution factors outlined above. Any significant beat or miss relative to these estimates will likely trigger meaningful stock price movement on the results day.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Technical_Analysis_%E2%80%94_Aurobindo_Pharma_Share_Price_Levels\"><\/span><strong>Technical Analysis \u2014 Aurobindo Pharma Share Price Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><ul class=\"wp-block-list\"><li>Current Market Price: Rs.1,010 on NSE<\/li>\n\n<li>52-Week High: Rs.Rs.1,450 | 52-Week Low: Rs.Rs.940<\/li>\n\n<li>The stock is trading below its 52-week high levels, reflecting the market&#8217;s current risk-reward assessment<\/li>\n\n<li>Key resistance: Monitor the 52-week high at Rs.Rs.1,450 as the near-term upside ceiling<\/li>\n\n<li>Key support: The 52-week low at Rs.Rs.940 represents the critical downside risk level to watch<\/li><\/ul><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Aurobindo Pharma&#8217;s live price, charts, and receive SEBI-backed research alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Aurobindo_Pharma_Share_Price_Target_%E2%80%94_Analyst_Estimates\"><\/span><strong>Aurobindo Pharma Share Price Target \u2014 Analyst Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Subscribe to Univest Pro for Premium Aurobindo Pharma Research and Analysis<\/strong><\/a><\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Short-Term_Target_3%E2%80%936_months\"><\/span><strong>Short-Term Target (3\u20136 months)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In the near term, Aurobindo Pharma&#8217;s share price will be primarily driven by the Q4 FY26 results outcome relative to estimates. A beat on revenue or PAT, combined with positive management guidance for FY27, could drive the stock toward the higher end of the short-term range of Rs.1,010\u20131,150. A miss or cautious guidance would test the lower end and potentially the 52-week lows.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"12-Month_Analyst_Consensus_Target\"><\/span><strong>12-Month Analyst Consensus Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The analyst consensus 12-month price target for Aurobindo Pharma is Rs.1,050\u20131,320, with most brokerages maintaining a Buy rating. This implies meaningful upside\/downside from the current market price of Rs.1,010. Target achievement is contingent on Q4 FY26 results meeting expectations and FY27 guidance being constructive.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Long-Term_View_FY27%E2%80%93FY28\"><\/span><strong>Long-Term View (FY27\u2013FY28)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Longer-term, Aurobindo Pharma&#8217;s share price trajectory will depend on sector growth trends, market share dynamics, management execution quality, and India&#8217;s overall macroeconomic environment. Investors with a 2-3 year horizon should evaluate the company on its fundamental business quality \u2014 ROCE trends, free cash flow generation, and balance sheet health \u2014 rather than short-term quarterly movements.<\/p><p>Explore Aurobindo Pharma&#8217;s historical financials, ROCE trends, and peer comparison on the <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_to_Watch_on_Results_Day\"><\/span><strong>What to Watch on Results Day<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><ul class=\"wp-block-list\"><li>Revenue and PAT numbers relative to estimates \u2014 any material beat or miss will be the primary price driver<\/li>\n\n<li>US revenue performance and new product approvals pipeline<\/li>\n\n<li>Dividend announcement \u2014 watch for final or special dividend declaration<\/li>\n\n<li>Management commentary on macro headwinds \u2014 US tariffs, crude prices, rural demand, or sector-specific challenges<\/li>\n\n<li>FY27 revenue\/earnings guidance \u2014 the single most important forward-looking data point for stock rerating<\/li><\/ul><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Aurobindo Pharma&#8217;s Q4 FY26 results on May 5, 2026 are one of the key earnings events for India&#8217;s Pharma sector in the April\u2013May 2026 results season. With the stock trading at Rs.1,010 and analyst targets pointing to Rs.1,050\u20131,320 over 12 months (Buy consensus), the Q4 FY26 outcome will be a critical catalyst for determining whether the stock achieves or delays its analyst-implied upside. Monitor the Univest research platform for real-time commentary, post-result analysis, and updated price targets after the results are declared.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_is_Aurobindo_Pharma_Q4_FY26_results_date\"><\/span><strong>When is Aurobindo Pharma Q4 FY26 results date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Aurobindo Pharma is scheduled to announce its Q4 FY26 (January\u2013March 2026) financial results on May 5, 2026. The board meeting will consider and approve the audited financial statements for Q4 FY26 and the full year FY26. The trading window for designated employees will be closed until 48 hours after the results announcement. Check the BSE\/NSE filing portal for exact timings on the day.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Aurobindo_Pharma_Q4_FY26_revenue_estimate\"><\/span><strong>What is the Aurobindo Pharma Q4 FY26 revenue estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analyst consensus estimates for Aurobindo Pharma&#8217;s Q4 FY26 revenue stand at Rs.7,400\u20137,800 Cr. This compares with Q3 FY26 actual revenue of Rs.7,249 Cr. The Q4 FY26 estimate reflects analyst expectations based on sector trends, management commentary in the Q3 FY26 earnings call, and macro environment assessment. Actual Q4 FY26 revenue may differ from these estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Aurobindo_Pharma_share_price_target\"><\/span><strong>What is the Aurobindo Pharma share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The analyst consensus 12-month price target for Aurobindo Pharma is Rs.1,050\u20131,320, with brokerages maintaining a Buy rating. Short-term target range is Rs.1,010\u20131,150. These targets are based on current fundamentals, sector outlook, and macro assumptions as of April 2026. Targets are subject to revision based on Q4 FY26 results and FY27 guidance.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Aurobindo_Pharma_a_good_buy_before_Q4_results\"><\/span><strong>Is Aurobindo Pharma a good buy before Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Investing ahead of quarterly results carries earnings risk \u2014 stocks can fall sharply on results misses regardless of prior technical setup. The appropriate approach is to assess whether the stock offers a good risk-reward at current levels relative to both the bull case (beat + positive guidance) and the bear case (miss + cautious commentary). Consult a SEBI-registered financial advisor to evaluate Aurobindo Pharma relative to your portfolio and risk tolerance before making any investment decision.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_should_I_watch_for_in_Aurobindo_Pharma_Q4_FY26_results\"><\/span><strong>What should I watch for in Aurobindo Pharma Q4 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Key metrics to monitor: Revenue performance vs estimate of Rs.7,400\u20137,800 Cr; PAT vs estimate of Rs.680\u2013750 Cr; management guidance for FY27; US revenue and pipeline updates; dividend declaration; and management commentary on macro headwinds.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Where_can_I_find_Aurobindo_Pharma_Q4_FY26_results\"><\/span><strong>Where can I find Aurobindo Pharma Q4 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Aurobindo Pharma&#8217;s Q4 FY26 results will be available on the BSE (bseindia.com) and NSE (nseindia.com) filing portals immediately after the board meeting on May 5, 2026. The company will also publish results on its investor relations website. For real-time analysis, expert commentary, and updated price targets post-results, download the <a href=\"https:\/\/univest.in\/user\/log-in\">Univest app<\/a>.<\/p><p>Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice or a stock recommendation. All estimates, analyst targets, and financial projections mentioned are based on publicly available data as of April 2026 and are subject to change. Investing in stocks involves market risk \u2014 you may lose part or all of your capital. Please consult a SEBI-registered financial advisor before making any investment decisions. Past performance does not guarantee future results.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/mphasis-q4-results-2026\">Mphasis Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/mastek-q4-results-2026\">Mastek Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/cyient-q4-results-2026\">Cyient Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/kpit-technologies-q4-results-2026\">KPIT Technologies Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/zensar-technologies-q4-results-2026\">Zensar Technologies Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Get Free Investment Predictions and Aurobindo Pharma Research at Univest Aurobindo Pharma is scheduled to announce its Q4 FY26 (January\u2013March 2026) financial results on May 5, 2026. As of April 2026, the stock trades around Rs.1,010 on NSE with a market capitalisation of Rs.59,200 Cr. The 52-week range is Rs.Rs.940 (low) to Rs.Rs.1,450 (high), and<\/p>\n","protected":false},"author":29,"featured_media":66863,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858],"class_list":["post-66860","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results"],"metadata":{"_edit_lock":["1775208880:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:6:{s:62:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-174.jpeg\";a:2:{s:2:\"id\";i:66861;s:11:\"source_type\";s:13:\"media-library\";}s:94:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/03145906\/image-174.jpeg\";a:2:{s:2:\"id\";i:66861;s:11:\"source_type\";s:13:\"media-library\";}s:62:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-175.jpeg\";a:2:{s:2:\"id\";i:66862;s:11:\"source_type\";s:13:\"media-library\";}s:94:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/03145906\/image-175.jpeg\";a:2:{s:2:\"id\";i:66862;s:11:\"source_type\";s:13:\"media-library\";}s:62:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-177.jpeg\";a:2:{s:2:\"id\";i:66868;s:11:\"source_type\";s:13:\"media-library\";}s:94:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/03150626\/image-177.jpeg\";a:2:{s:2:\"id\";i:66868;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["71"],"rank_math_description":["Aurobindo Pharma Q4 results on May 5, 2026. Revenue estimate Rs.7,400\u20137,800 Cr, PAT estimate Rs.680\u2013750 Cr. Analyst target Rs.1,050\u20131,320. Key catalysts and risks."],"rank_math_title":["Aurobindo Pharma Q4 Results 2026: Date, Revenue Estimates and Share Price Target | Univest"],"rank_math_focus_keyword":["Aurobindo Pharma Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["66863"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/03150244\/Aurobindo-Pharma.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/66860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=66860"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/66860\/revisions"}],"predecessor-version":[{"id":66864,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/66860\/revisions\/66864"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/66863"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=66860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=66860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=66860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}